BIOHIT HealthCare has announced a new partnership with Celltrion Healthcare UK, providing point-of-care assays for the Celltrion Connect Dedicated Homecare Service, which is designed to support patients with inflammatory bowel disease (IBD) and their healthcare providers.
BIOHIT will be supplying the Preventis SmarTest Calprotectin Home test – a digital self-test system that combines a faecal calprotectin test with a smartphone app to help patients to monitor their condition in the comfort of their own homes.
The new service has been set up in response to NHS demands and offers a unique 360-degree care package to support IBD patients who have been prescribed Remsima SC (infliximab). It also provides ongoing education and support from fully dedicated, experienced, specialist nurses – to ensure patients get the most from their medication and achieve the best possible outcomes while on this therapy – and high-quality prescription management, dispensing and delivery services.
As part of this care initiative, the SmarTest rapid lateral flow device will be delivered to patients three times a year for instant snapshots of their disease. A quantitative measurement of faecal calprotectin levels and assessment of disease activity via patient-reported symptoms are recorded using the SmarTest Calprotectin Home app. The results are then automatically sent to the patient’s clinical team within the associated healthcare organisation, so that clinicians can monitor their patients’ conditions remotely with confidence.
Graham Johnson, Managing Director at BIOHIT Healthcare, commented: “We are delighted to support the Celltrion Connect programme with SmarTest, an intuitive self-test that is ideally suited to this model of care to truly benefit IBD patient management and outcomes.”
For more information about the SmarTest Calprotectin Home test, please visit biohithealthcare.co.uk/biohit-product/smartest-calprotectin-home.